Leveraging High Quality Data to Discover Drugs

The IP & Science Business of Thomson Reuters has announced a strategic initiative with NuMedii. The companies will leverage high-quality data, knowledge and predictive technologies to identify therapeutic candidates with the greatest probability for clinical success.